[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 77, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 47, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1041809, "exercisedValue": 0, "unexercisedValue": 6715049}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 55, "title": "Chief Administrative Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 710304, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Dr. Antoine  Yver M.D., M.Sc.", "age": 65, "title": "Executive VP & Chairman of Development", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 773138, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 52, "title": "Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 52, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 42, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 55, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mario Alberto Accardi Ph.D.", "title": "President of the Orexin Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harris L. Rotman Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.89, "open": 8.83, "dayLow": 8.78, "dayHigh": 8.99, "regularMarketPreviousClose": 8.89, "regularMarketOpen": 8.83, "regularMarketDayLow": 8.78, "regularMarketDayHigh": 8.99, "beta": 1.399, "forwardPE": -5.1666665, "volume": 184865, "regularMarketVolume": 184865, "averageVolume": 216425, "averageVolume10days": 299430, "averageDailyVolume10Day": 299430, "bid": 8.93, "ask": 8.99, "bidSize": 400, "askSize": 400, "marketCap": 1016265536, "fiftyTwoWeekLow": 5.15, "fiftyTwoWeekHigh": 12.45, "priceToSalesTrailing12Months": 148.29498, "fiftyDayAverage": 9.1601, "twoHundredDayAverage": 8.381375, "currency": "USD", "enterpriseValue": 872162752, "floatShares": 71076568, "sharesOutstanding": 113044000, "sharesShort": 1247306, "sharesShortPriorMonth": 1793755, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.011, "heldPercentInsiders": 0.02049, "heldPercentInstitutions": 0.77359, "shortRatio": 8.04, "shortPercentOfFloat": 0.014099999, "impliedSharesOutstanding": 113044000, "bookValue": 2.141, "priceToBook": 4.198972, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -138416992, "trailingEps": -1.42, "forwardEps": -1.74, "enterpriseToRevenue": 127.267, "enterpriseToEbitda": -5.515, "52WeekChange": 0.52372885, "SandP52WeekChange": 0.24598539, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.99, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 14.2, "targetMedianPrice": 14.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 230176992, "totalCashPerShare": 2.036, "ebitda": -158136992, "totalDebt": 86072000, "quickRatio": 9.745, "currentRatio": 10.369, "totalRevenue": 6853000, "debtToEquity": 40.003, "revenuePerShare": 0.07, "returnOnAssets": -0.27064, "returnOnEquity": -0.54449004, "freeCashflow": -92709248, "operatingCashflow": -149790000, "grossMargins": 1.0, "operatingMargins": -23.127972, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]